Technavio Announces the Publication of its Research Report Global Alopecia Drugs Market 2016-2020
Technavio recognizes the following companies as the key players in the global alopecia drugs market: GlaxoSmithKline, Johnson & Johnson, and Merck
Other Prominent Vendors in the market are: Aclaris Therapeutics, Actelion Pharmaceuticals, Almirall, AndroScience, Anterios, Aqua Pharmaceuticals, Astellas Pharma, Bayer HealthCare, BERG Health, BiologicsMD, BioPharmX, Celtaxsys, Cipher Pharmaceuticals, Concert Pharmaceuticals, Cosmo Pharmaceuticals, Dermira, Elorac, F. Hoffmann-La Roche, Foamix, Guthy-Renker, Helix BioMedix, Hygeia Therapeutics, Hyundai Pharm, Incyte, Kasiak Research, Kythera Biopharmaceuticals, Mylan, NovaLead Pharma, Novan, Oculus Innovative Sciences, Paratek Pharmaceuticals, Photocure, Polichem, Promius Pharma, Ranbaxy Laboratories, Reckitt Benckiser, Regience, Samumed, RepliCel, Skinvisible Pharmaceuticals, Teva Pharmaceutical, Versapharm, and XBiotech
Browse full report with TOC @ https://marketreportscenter.com/reports/470080/global-alopecia-drugs-market-2016-2020
Commenting on the report, an analyst from Technavios team said: The use of regenerative medicine is an emerging treatment option for the treatment of alopecia. These regenerative medicines help in the healing process by replacement or regeneration of the human cells, tissues or organs, and thus assist in establishing the normal function. Cell therapy and growth factor therapy are some of the regenerative techniques included in the treatment of alopecia. Companies such as RepliCel, Kyocera, and RIKEN Organ Technologies. are engaged in the development of regenerative medicines for the treatment of alopecia. Apart from these companies, various research organizations such as Mayo Clinic, Center for Regenerative Medicine are also engaged in the development of regenerative medicines.
According to the report, the alopecia market has a huge unmet need in terms of approved therapies. Globally, the market has only two approved drugs, one (minoxidil) being topical in nature whereas, other (finasteride) being oral. However, these two drugs have a huge success story with the individuals affected with alopecia and command nearly 80% of the market share. Lately, the Japanese, South Korean, and Australian market have seen the entry of AVODART, impact of which is yet to be quantified by the market. However, considering the efficacy and safety of this drug, once approved for the US and the EU market, the alopecia drug market should witness stronger growth on a global scale.
Further, the report states that the increasing incidence of alopecia worldwide is providing a perfect growth platform to the market. However, as currently, the market has only one approved therapy, there is a huge unmet need to be addressed. Additionally, considering the complex etiology of alopecia and its idiopathic occurrence, the development of any new formula is always in dispute. Several theories exist regarding the pathogenesis of the disease, including being labeled as an autoimmune disorder caused by genetic mutation; however, none of the theories provided exact pathophysiology of alopecia. This further restrains the prospects of new therapies coming into the market. Additional factors such as hormonal disorders and environmental-related issues like pollution play an important role in developing this disease.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Request A Sample copy of This Report @ https://marketreportscenter.com/request-sample/470080
About Alopecia Drugs
Alopecia is a loss of hair and can occur at any age across the genders. The exact cause of this disorder is unknown, but many factors are assumed to be responsible for developing alopecia. Few of the primary ones are a sedentary lifestyle, unhealthy diets, and side effects of certain medical treatments. Moreover, hormonal imbalance and aging increase the probability of developing a chronic disease like cancer, arthritis, depression, and hypertension, which would also lead to hair loss, especially among middle-to-late-aged people.
Technavios analysts forecast the global alopecia drugs market to grow at a CAGR of 5.02% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global alopecia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of alopecia drugs.
The market is divided into the following segments based on geography:
Technavio’s report, Global Alopecia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
To Get Discount On The Report @ https://marketreportscenter.com/request-discount/470080
Connect for more details:
Market Reports Center